CalciMedica, Inc. reported a net income of $4.976 million for the first quarter of 2026, a significant turnaround from a net loss of $5.042 million in the same period of the previous year. The company’s total operating expenses decreased to $5.611 million from $6.497 million year-over-year, primarily due to reduced research and development costs, which fell by 17% to $3.485 million. This decline was attributed to lower spending on preclinical studies and clinical trial-related activities, as well as a reduction in chemistry, manufacturing, and controls expenses.
The company’s financial position showed a decrease in cash and cash equivalents, which stood at $8.164 million as of March 31, 2026, down from $11.520 million at the end of 2025. Total current assets also declined to $8.555 million from $13.530 million, while total liabilities decreased significantly to $9.713 million from $20.232 million. The reduction in liabilities was largely due to a decrease in the fair value of the promissory note and warrant liabilities, which fell from $17.700 million to $6.900 million. CalciMedica's accumulated deficit improved to $184.350 million from $189.326 million.
Strategically, CalciMedica has been focused on advancing its lead product candidate, Auxora, a CRAC channel inhibitor, through clinical trials. The company paused enrollment in the KOURAGE Phase 2 trial due to safety concerns but continues to engage with the FDA regarding the design of a potential pivotal program for Auxora in acute pancreatitis. The company is also developing CM5480, an oral CRAC channel inhibitor, with an Investigational New Drug application anticipated in 2027, contingent on securing additional funding.
Operationally, CalciMedica's employee headcount and engagement metrics have not been disclosed in the filing. However, the company has indicated that it expects to incur significant expenses as it continues to develop its product candidates and expand its workforce. The company has raised a total of $193.9 million since its inception through various financing activities, including a recent $10 million loan agreement, which is expected to support its operations into the fourth quarter of 2026. Despite this, there is substantial doubt about the company's ability to continue as a going concern without additional capital, as its current cash reserves may not be sufficient to fund ongoing operations and development activities.
About CalciMedica, Inc.
CalciMedica is a clinical-stage biopharmaceutical company developing innovative therapeutics targeting calcium release-activated calcium (CRAC) channels. Its lead product, Auxora, is a selective IV CRAC channel inhibitor aimed at treating acute critical illnesses such as pancreatitis, kidney injury, and respiratory failure. The company's dual anti-inflammatory and tissue-protective approach addresses unmet needs in severe inflammatory and immunologic diseases across acute and chronic markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.